List of Excipients in Branded Drug BUPIVACAINE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HF Acquisition Co LLC DBA HealthFirst	BUPIVACAINE HCL	bupivacaine hcl	51662-1592	HYDROCHLORIC ACID
HF Acquisition Co LLC DBA HealthFirst	BUPIVACAINE HCL	bupivacaine hcl	51662-1592	METHYLPARABEN
HF Acquisition Co LLC DBA HealthFirst	BUPIVACAINE HCL	bupivacaine hcl	51662-1592	SODIUM CHLORIDE
HF Acquisition Co LLC DBA HealthFirst	BUPIVACAINE HCL	bupivacaine hcl	51662-1592	SODIUM HYDROXIDE

Generic Drugs Containing BUPIVACAINE

Company	Ingredient	NDC	Excipient
Hospira Inc	bupivacaine hydrochloride in dextrose	0409-3613	ANHYDROUS DEXTROSE
Hospira Inc	bupivacaine hydrochloride in dextrose	0409-3613	HYDROCHLORIC ACID
Hospira Inc	bupivacaine hydrochloride in dextrose	0409-3613	SODIUM HYDROXIDE
HF Acquisition Co LLC DBA HealthFirst	bupivacaine hci	51662-1581	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in BUPIVACAINE?

# Of NDCs	Excipient
1	ANHYDROUS DEXTROSE
1	HYDROCHLORIC ACID
1	SODIUM HYDROXIDE

Bupivacaine Excipient Strategy and Commercial Opportunities

Last updated: October 25, 2026

Bupivacaine is a mature local anesthetic with limited opportunity in the active ingredient itself. The commercial value is concentrated in excipient-enabled delivery: preservative-free ready-to-use injections, long-acting depot systems, liposomal formulations, combination products, and manufacturing platforms that reduce dosing frequency or opioid use. Conventional bupivacaine hydrochloride is broadly generic, while Exparel and Zynrelef retain differentiated commercial positions through delivery technology and formulation-related intellectual property.

What bupivacaine formulations are commercially available?

Bupivacaine is marketed mainly as bupivacaine hydrochloride injection, liposomal bupivacaine, and a fixed-dose bupivacaine-meloxicam extended-release product.

Product	Active ingredients	Delivery format	Commercial positioning
Generic bupivacaine HCl injection	Bupivacaine hydrochloride	Injectable solution	Low-cost standard of care
Marcaine / Sensorcaine	Bupivacaine hydrochloride	Injectable solution	Reference and legacy brands
Exparel	Bupivacaine	Multivesicular liposome injection	Extended local analgesia
Zynrelef	Bupivacaine hydrochloride and meloxicam	Extended-release solution	Postoperative pain control
Compounded preparations	Usually bupivacaine HCl	Variable	Hospital and specialty use

The principal approved indications for conventional bupivacaine include local infiltration, peripheral nerve block, sympathetic nerve block, and caudal or epidural block, depending on concentration and product labeling. Exparel is approved for specific local and regional analgesia uses, including surgical-site infiltration and selected nerve blocks. Zynrelef is approved for postoperative analgesia in adults after certain lower-extremity, small-to-medium abdominal-wall, and foot-and-ankle procedures. Product-specific labeling controls the permitted routes and indications.[1-3]

What excipients are used in conventional bupivacaine injection?

Conventional bupivacaine injection uses a relatively simple aqueous excipient system.

Typical excipient components include:

• Water for injection
• Sodium chloride for isotonicity
• Hydrochloric acid or sodium hydroxide for pH adjustment
• Preservatives in selected multidose presentations, commonly a paraben
• Nitrogen or other headspace controls in certain packaging configurations

The exact composition varies by manufacturer, concentration, route, container, and preservative status. Single-dose presentations generally have a stronger commercial position in epidural, obstetric, pediatric, and regional anesthesia settings because hospitals seek to avoid preservative exposure where the label or institutional policy limits preservative-containing products.

The key excipient issues are not formulation complexity but product usability and quality:

1. Chemical stability over the labeled shelf life.
2. Compatibility with syringes, elastomeric components, needles, and infusion systems.
3. Low particulate burden.
4. Reliable osmolality and pH.
5. Absence of antimicrobial preservative where clinically preferred.
6. Ready-to-use packaging that reduces pharmacy preparation.

Which excipient opportunities exist in standard bupivacaine injection?

The most practical opportunity is a differentiated generic rather than a novel excipient claim. Potential products include:

• Preservative-free single-dose vials in multiple concentrations.
• Ready-to-administer prefilled syringes.
• Premixed bags for selected infusion or regional anesthesia workflows.
• Low-volume presentations for ambulatory surgery centers.
• Products optimized for compatibility with nerve-block pumps.
• Unit-dose packaging with barcode, tamper evidence, and anesthesia-cart integration.
• Formulations with reduced extractables and leachables for long storage.

These products may qualify for ANDA development when they meet the relevant sameness and bioequivalence requirements. A formulation that materially changes route, release profile, excipient safety, or clinical use may require a 505(b)(2) pathway rather than a standard ANDA.[4]

How does Exparel use excipients to extend bupivacaine release?

Exparel uses a multivesicular liposome delivery system. Bupivacaine is incorporated into particles composed of multiple internal aqueous chambers separated by lipid membranes. The structure releases drug over an extended period after injection.

The labeled excipient system includes lipid and structural components such as:

• 1,2-dierucoyl-sn-glycero-3-phosphocholine
• 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)
• Cholesterol
• Tricaprylin
• Water and pH-adjusting agents

The formulation is materially different from a conventional bupivacaine solution. The lipids control particle architecture, drug loading, release behavior, injectability, and storage stability. The product cannot be treated as a simple substitution of a conventional surfactant or cosolvent.

Exparel's commercial value comes from the delivery platform, not from a new bupivacaine molecule. The excipient system supports:

• Extended local exposure.
• Reduced need for repeated infiltration in selected procedures.
• Use in surgical-site infiltration.
• Use in selected nerve blocks.
• A premium price compared with generic bupivacaine solution.

The main development barriers are particle-size control, encapsulation efficiency, release testing, sterilization, scale-up, and batch-to-batch consistency. Liposomal injectables also require more extensive characterization than conventional solutions, including assessment of free versus encapsulated drug, morphology, particle distribution, lipid degradation, and in-use stability.

What patent rights protect Exparel?

Pacira Pharmaceuticals developed and commercialized Exparel. The patent estate has included patents directed to multivesicular liposomes, bupivacaine-containing compositions, manufacturing processes, and methods of use. Key publicly reported Exparel-related U.S. patents have included U.S. Patent Nos. 8,182,835, 8,337,856, 8,545,968, 8,795,712, 8,992,486, and 9,192,644, among others.[5]

Patent term and Orange Book listing status must be assessed patent by patent. Some patents may expire earlier than others, and regulatory exclusivity is separate from patent term. A generic or 505(b)(2) applicant must evaluate composition, manufacturing, release-profile, and method-of-use claims rather than relying only on the expiration of a single formulation patent.

What excipients are used in Zynrelef?

Zynrelef combines bupivacaine hydrochloride with meloxicam in an extended-release delivery system. The product is designed to release both active ingredients locally after application to the surgical site.

Its commercial differentiation depends on:

• Local co-delivery of a local anesthetic and an anti-inflammatory analgesic.
• Extended drug release from a biodegradable polymer system.
• Single-application administration during surgery.
• Reduced reliance on repeated local-anesthetic dosing in selected procedures.

The formulation uses a biodegradable polymer-based delivery matrix and nonaqueous formulation components. The exact formulation technology is proprietary and is linked to Heron Therapeutics' Biochronomer platform. The product must maintain the stability of both bupivacaine and meloxicam while controlling polymer degradation and release kinetics.[3,6]

Zynrelef illustrates a higher-value excipient strategy than conventional bupivacaine. The formulation protects not only delivery characteristics but also the combination-product concept. A competing product would need to address the active-ingredient combination, dosage form, polymer system, manufacturing process, release profile, and method-of-use claims.

When does bupivacaine lose exclusivity?

The original bupivacaine molecule and conventional injectable presentations have long lost basic compound exclusivity. Generic bupivacaine hydrochloride products are approved in the United States and compete primarily on price, supply reliability, concentration range, preservative status, and packaging.

The exclusivity position differs by product:

Product type	Basic compound status	Main remaining protection
Conventional bupivacaine HCl	Generic	Product quality, supply, packaging, limited formulation claims
Exparel	Active ingredient is mature	Liposome composition, manufacturing, release profile, methods of use
Zynrelef	Mature actives	Combination, polymer delivery, manufacturing, and methods of use
New bupivacaine depot	New product candidate	505(b)(2) regulatory exclusivity and formulation patents

A generic version of conventional bupivacaine does not create a biosimilar issue. Bupivacaine is a chemically synthesized small molecule, not a biologic. The relevant pathways are ANDA, 505(b)(2), and, in limited cases, a new drug application.

What is the Orange Book status of bupivacaine products?

Conventional bupivacaine injection products are listed in the FDA Orange Book through multiple abbreviated applications. Orange Book listings identify approved products, therapeutic equivalence codes, patents, and exclusivity where applicable.[7]

Exparel and Zynrelef have been listed as branded prescription products with product-specific patent and exclusivity considerations. The Orange Book analysis should separate:

• Listed patents for the reference product.
• Patent expiration dates.
• Pediatric exclusivity.
• New chemical entity exclusivity, if applicable.
• Three-year clinical-investigation exclusivity.
• Approved indications subject to method-of-use claims.
• Whether a patent is relevant to the proposed generic label.

A patent listing does not establish infringement. An ANDA applicant may submit a Paragraph IV certification arguing that a listed patent is invalid, unenforceable, or not infringed. The reference-product sponsor may then bring patent litigation, generally triggering a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and litigation developments.[8]

Which companies are challenging bupivacaine exclusivity?

Competition is fragmented across three groups:

Generic injectable manufacturers

Companies such as Hikma, Fresenius Kabi, Pfizer, Eugia, Sagent, and other injectable manufacturers have marketed or sought approval for conventional bupivacaine products in various concentrations and package sizes. Competition is usually based on institutional contracts, manufacturing reliability, shortage performance, and price.

Long-acting local-anesthetic developers

Pacira has established the leading commercial position in liposomal bupivacaine through Exparel. Heron has commercialized Zynrelef as a combination extended-release product. Other developers have pursued sustained-release local anesthetics using liposomes, biodegradable polymers, microspheres, hydrogels, and in situ depots.

Hospital and specialty compounders

Compounding pharmacies may supply customized concentrations or combinations, but compounded products do not generally provide the same regulatory, manufacturing, or patent position as FDA-approved products. Their use is constrained by state law, federal compounding requirements, institutional controls, and product-specific clinical policies.

Public litigation and Paragraph IV activity should be checked against current FDA Orange Book listings, PACER records, and sponsor disclosures because the relevant patents and settlement terms change over time.[7-9]

What formulation patents protect bupivacaine products?

The strongest patent opportunities generally fall into five categories.

Liposome composition patents

These claims may cover lipid identity, lipid ratios, particle architecture, encapsulation, and bupivacaine loading. They are relevant to Exparel-type products.

Polymer depot patents

These claims may cover polymer composition, molecular weight, degradation rate, solvent system, implant geometry, and release kinetics. They are relevant to products such as Zynrelef and other extended-release depots.

Combination-product patents

Claims may cover bupivacaine with meloxicam, dexamethasone, clonidine, dexmedetomidine, or other analgesic and anti-inflammatory agents. Combination claims can create additional barriers when they match the approved clinical use.

Manufacturing patents

Manufacturing claims may cover liposome formation, homogenization, sterilization, filtration, polymer dissolution, aseptic filling, and release testing. These claims can be commercially important even when a competitor designs around the composition claims.

Method-of-use patents

Potential claims include specific orthopedic, abdominal, cesarean, dental, nerve-block, or surgical-site uses; dose ranges; timing of administration; and coadministration with other analgesics. Method-of-use patents are most relevant when the generic applicant seeks the same indication or when the use is difficult to carve out of the label.

How strong is the bupivacaine patent estate?

The patent strength differs sharply by segment.

Segment	Patent strength	Primary reason
Conventional bupivacaine solution	Low	Mature composition and simple formulation
Preservative-free bupivacaine	Low to moderate	Limited differentiation unless supported by packaging or stability claims
Liposomal bupivacaine	High	Complex composition and manufacturing architecture
Polymer-based bupivacaine depot	Moderate to high	Delivery system and release-control claims
Bupivacaine combinations	Moderate to high	Combination, formulation, and method-of-use protection
Prefilled syringe or device presentation	Moderate	Device, container, and human-factors claims

The strongest commercial defenses are usually cumulative. A sponsor with composition, process, release-profile, and method-of-use patents has more options than a sponsor relying on a single broad formulation claim.

What Paragraph IV risks exist for Exparel and Zynrelef?

Paragraph IV risk is highest when a product has substantial sales, an identifiable formulation target, and a patent estate approaching the end of its effective commercial life.

For an Exparel-type product, a challenger would likely examine:

• Whether the proposed liposome has the same or equivalent structural characteristics.
• Whether the proposed product meets the relevant pharmaceutical-equivalence standard.
• Whether manufacturing claims are infringed.
• Whether the applicant can avoid method-of-use claims through a skinny label.
• Whether differences in lipid composition avoid composition claims while preserving clinical performance.

For Zynrelef, a challenger would examine:

• The bupivacaine-meloxicam combination.
• The polymer matrix and solvent system.
• Release kinetics for both active ingredients.
• Surgical-site administration claims.
• Manufacturing and filling processes.
• Whether a noninfringing alternative can deliver equivalent clinical performance.

Patent settlements may include delayed launch dates, licenses, covenants not to sue, authorized generic rights, or restrictions tied to specific indications. Settlement terms should be evaluated against FTC reporting, court filings, FDA listings, and company disclosures rather than inferred from a patent expiration date alone.

What FDA regulatory pathway applies to new bupivacaine excipient products?

The pathway depends on the degree of difference from the reference product.

ANDA

An ANDA is appropriate for a conventional generic bupivacaine injection that matches the reference product in active ingredient, dosage form, route, strength, and key product characteristics. Excipient differences may be acceptable if they do not affect safety, efficacy, quality, or bioequivalence.

505(b)(2)

A 505(b)(2) application is more suitable for:

• Extended-release bupivacaine.
• A new liposomal or polymeric delivery system.
• A new combination with another analgesic.
• A new route or surgical use.
• A substantially different excipient system.
• A product requiring new clinical or pharmacokinetic evidence.

The 505(b)(2) route can generate three-year clinical-investigation exclusivity for certain approved changes, but it does not provide the five-year new chemical entity exclusivity associated with a new active moiety.

Medical-device combination considerations

Prefilled syringes, delivery pumps, wound applicators, and depot delivery devices may create combination-product issues. Human-factors testing, device compatibility, dose accuracy, and container-closure performance can affect approval timing and commercial adoption.

What commercial opportunities exist for bupivacaine excipients?

The highest-value opportunities are linked to clinical workflow and total treatment cost.

Preservative-free ready-to-use products

Hospitals continue to value unit-dose formats that reduce preparation time, medication errors, and waste. A differentiated preservative-free product can compete even when the active ingredient is commoditized.

Long-acting regional anesthesia

Extended-release bupivacaine remains the largest formulation opportunity. Products that provide predictable analgesia over several days may command premium pricing if they reduce rescue opioid use, nursing interventions, or unplanned admissions.

Combination analgesia

Bupivacaine combined with an anti-inflammatory or adjunctive analgesic can improve postoperative pain control without requiring a new local-anesthetic molecule. The principal risks are regulatory complexity, compatibility, dose optimization, and proof of clinical benefit.

Ambulatory surgery

Small-volume, room-temperature-stable, ready-to-use formats are suited to ambulatory surgical centers. Commercial success depends on procedure-specific evidence and simple administration.

Dental and office-based procedures

A product with lower preparation burden and predictable duration may compete in dental, plastic-surgery, podiatry, and office-based intervention markets. The product must justify its price against inexpensive conventional bupivacaine.

Manufacturing technology licensing

Licensing opportunities exist in:

• Liposome manufacturing.
• Biodegradable polymer depots.
• Sterile aseptic filling.
• Particle-size control.
• Release testing.
• Container systems that minimize adsorption and leachables.

Technology owners can monetize platforms through regional licenses, contract development and manufacturing agreements, or co-development with branded generic and specialty-pharmaceutical companies.

How does bupivacaine compare with competing local anesthetics?

Drug	Duration profile	Generic status	Formulation opportunity
Bupivacaine	Long acting	Mature generic	Strongest opportunity in depot and combination delivery
Ropivacaine	Long acting	Generic in many markets	Potential for sustained-release systems
Lidocaine	Short to intermediate	Mature generic	High-volume, lower-margin products
Mepivacaine	Intermediate	Generic	Limited premium formulation space
Chloroprocaine	Short acting	More specialized	Opportunity in preservative-free and obstetric formats

Bupivacaine has a favorable base for delivery innovation because its conventional duration is already longer than lidocaine's, while extended-release products can target multi-day postoperative pain. The main competitive constraint is its cardiotoxicity risk at excessive systemic exposure, which makes controlled release and dose uniformity important technical objectives.[10]

What manufacturing and IP barriers affect new bupivacaine products?

The principal barriers include:

• Sterile manufacturing at commercial scale.
• Liposome or polymer particle reproducibility.
• Drug loading and release consistency.
• Control of free drug.
• Container-closure compatibility.
• Terminal sterilization limitations.
• Aseptic process validation.
• Long-term stability.
• In-use stability after dilution or mixing.
• Demonstration of local tolerability.
• Patent clearance for composition and manufacturing claims.

For conventional injections, manufacturing is relatively accessible, which drives price competition. For advanced delivery systems, the manufacturing process may be as defensible as the formulation itself. A developer that cannot reproduce release performance at scale will face regulatory and commercial barriers even if its patent position is strong.

What is the revenue exposure to bupivacaine formulation competition?

Generic bupivacaine revenue is exposed to price erosion and hospital purchasing concentration. Branded extended-release products have higher revenue exposure because their value depends on premium pricing and procedure-specific adoption.

Pacira reported 2023 net product sales of approximately $672.9 million for Exparel, demonstrating the commercial scale available for differentiated bupivacaine delivery.[11] The revenue base remains exposed to:

• Generic or follow-on liposomal competition.
• Hospital formulary restrictions.
• Clinical debate over duration and opioid-sparing benefit.
• Procedure-specific reimbursement.
• Patent litigation.
• New local-anesthetic depots.
• Lower-cost multimodal analgesia protocols.

Zynrelef competes in a similar postoperative market but uses a combination-product model. Its commercial risk is tied to adoption of the full bupivacaine-meloxicam product rather than substitution within the conventional bupivacaine market.

Key Takeaways

• Conventional bupivacaine injection is a mature generic market with limited composition-level exclusivity.
• The strongest commercial opportunities involve liposomes, biodegradable polymers, ready-to-use packaging, and combination analgesia.
• Exparel's differentiation comes from its multivesicular liposome system and related formulation and manufacturing patents.
• Zynrelef uses a bupivacaine-meloxicam extended-release platform with combination-product and delivery-system barriers.
• New conventional products generally fit the ANDA pathway; materially different delivery systems usually require 505(b)(2) development.
• Bupivacaine has no biosimilar risk because it is a synthetic small molecule.
• The most valuable IP generally combines composition, process, release-profile, and method-of-use claims.
• Manufacturing scale-up and release testing are major barriers for advanced bupivacaine delivery products.
• Commercial upside is greatest in postoperative pain, regional anesthesia, ambulatory surgery, and preservative-free unit-dose formats.

Frequently Asked Questions

Can a new preservative-free bupivacaine product receive patent protection?

Yes, but a basic preservative-free formulation is unlikely to support broad, durable protection by itself. Stronger claims may arise from a specific container system, stability profile, dosing format, device, or manufacturing process.

Is liposomal bupivacaine interchangeable with generic bupivacaine?

No. Liposomal bupivacaine has a different delivery system, dosing profile, handling requirements, and approved labeling. Therapeutic substitution depends on the product, indication, institutional policy, and applicable regulatory status.

Can bupivacaine be combined with dexamethasone or dexmedetomidine?

A developer may pursue such combinations, but the product would require compatibility, stability, local-tolerance, dose, and clinical evidence. The regulatory pathway would likely be more complex than a conventional bupivacaine ANDA.

Are excipient suppliers exposed to Exparel patent infringement?

Potentially. A supplier may face risk if it provides a component or process specifically claimed in an issued patent and the relevant legal requirements for contributory or induced infringement are met. Contract allocation of IP and indemnity risk is important.

What is the most attractive near-term bupivacaine product concept?

A preservative-free, ready-to-use, unit-dose product has the lowest technical risk. A long-acting depot or combination product has greater revenue potential but requires materially higher formulation, clinical, manufacturing, and patent investment.

References

1. U.S. Food and Drug Administration. (2023). Marcaine and Sensorcaine injection prescribing information.
2. U.S. Food and Drug Administration. (2024). Bupivacaine hydrochloride injection product labeling and approval information.
3. U.S. Food and Drug Administration. (2024). Zynrelef prescribing information.
4. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2).
5. U.S. Patent and Trademark Office. (n.d.). Patent records for bupivacaine multivesicular liposome products.
6. Heron Therapeutics, Inc. (2024). Zynrelef product and technology information.
7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
8. U.S. Food and Drug Administration. (2024). Paragraph IV certification and patent-listing provisions.
9. U.S. District Court records. (n.d.). Patent litigation involving Exparel and Zynrelef.
10. U.S. Food and Drug Administration. (2023). Bupivacaine hydrochloride clinical pharmacology and safety labeling.
11. Pacira BioSciences, Inc. (2024). 2023 annual report and Form 10-K.